60 Degrees Pharmaceuticals (SXTP) Non Operating Interest Expenses (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported Non Operating Interest Expenses for 5 consecutive years, with $1403.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 14.91% year-over-year to $1403.0 in Q2 2026; TTM through Jun 2026 was $7586.0, a 28.58% increase from a year earlier, with the FY2025 full-year figure at $7805.0, down 1.35% from the prior year.
• Non Operating Interest Expenses was $1403.0 for Q2 2026 at 60 Degrees Pharmaceuticals, up from $1389.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.2 million in Q3 2022 and troughed at $1221.0 in Q2 2025.
• A 5-year average of $325428.7 and a median of $3086.0 in 2025 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses plunged 99.88% in 2024 and surged 117.02% in 2025, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then slumped by 99.51% to $5446.0 in 2023, then plunged by 73.89% to $1422.0 in 2024, then soared by 117.02% to $3086.0 in 2025, then plunged by 54.54% to $1403.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $1403.0 (Q2 2026), $1389.0 (Q1 2026), and $3086.0 (Q4 2025), per Business Quant data.